This is a two-part, Phase I/II, open-label, global, multicenter study assessing the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) versus standard of care in participants with progressive metastatic castrate resistant prostate cancer (mCRPC).
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
This trial is no longer recruiting — here are similar active trials
Matched by cancer type/biomarker, currently recruiting.
Transperineal prostate biopsy is a safe and effective method of diagnosing prostate cancer. When performed under local anaesthesia in an outpatient setting, it can cause significant pain, particularly during the periprostatic nerve block - the injection of local anaesthetic around the prostate. Better pain management during this procedure may improve patient comfort and encourage wider use of the transperineal approach. Transcutaneous electrical nerve stimulation (TENS) is a non-invasive, low-cost method of pain relief that works by delivering mild electrical impulses through the skin. A preceding pilot study at our centre (n=84) found that TENS used alongside local anaesthesia was associated with significantly lower pain scores during periprostatic nerve block and biopsy sampling, with no device-related complications. This study aims to confirm these findings in a larger, formally powered, triple-blind, randomized controlled trial. Participants will be randomly assigned to receive either active TENS or sham TENS (electrodes applied but no electrical current delivered) in addition to standard local anaesthesia. Neither the participant nor the operating urologist will know which group the participant is in. Pain scores are written down by the participant himself, so nobody asks him for a number during the procedure. Stimulation may feel strong, weak or not noticeable at all, and feeling nothing does not mean a participant is in the inactive group. Pain intensity will be assessed at four stages of the procedure using a 0-10 numeric rating scale. Participants will be followed up at 30 days after the biopsy.
TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet) and nivolumab + relatlimab (triplet) and in combination with docetaxel and prednisone in participants with advanced solid tumors. In addition, the study will evaluate the effect of multiple dose administration of zanzalintinib on the single-dose pharmacokinetics of sensitive CYP3A4, CYP2C9, CYP2C19, or CYP1A2 substrates in participants with advanced solid tumors. In the Expansion Stage, the safety and efficacy of zanzalintinib as monotherapy and in combination therapy will be further evaluated in tumor-specific Expansion Cohorts.
About the trial
The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astellas or Medivation (i.e., parent study) which has completed, at a minimum, the primary analysis or the study specified evaluation period.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Obecnie otrzymujesz enzalutamid lub masz go otrzymywać w leczeniu raka prostaty w badaniu sponsorowanym przez Astellas lub Medivation i lekarz uważa, że dalsze leczenie jest dla Ciebie korzystne.
- •Możesz kontynuować dotychczasowe leczenie.
- •Jesteś w stanie połykać kapsułki enzalutamidu i stosować się do zasad badania.
- •Ty i Twoja partnerka (jeśli jest w wieku rozrodczym) musicie stosować dwie metody antykoncepcji (jedna bardzo skuteczna i jedna barierowa) przez cały czas trwania badania i przez 3 miesiące po jego zakończeniu.
- •Zgadzasz się nie oddawać nasienia podczas badania i przez co najmniej 3 miesiące po ostatniej dawce enzalutamidu.
- •Zgadzasz się nie brać udziału w innym badaniu klinicznym podczas leczenia.
✗ Disqualifies
- •Nie możesz być uczestnikiem badań zainicjowanych przez lekarza.
- •Badanie może nie być dostępne dla niektórych osób ze względu na lokalne przepisy (np. dotyczące zgody na przetwarzanie danych).
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 12, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (234)
Site US10052
Anchorage, United States
Site US10011
Tucson, United States
Site US10040
Los Angeles, United States
Site US10009
Los Angeles, United States
Site US10008
San Bernardino, United States
Site US10042
San Diego, United States
Site US10028
Stanford, United States
Site US10001
Aurora, United States
Site US10017
Denver, United States
Site US10050
Washington D.C., United States
Site US10049
Daytona Beach, United States
Site US10002
Chicago, United States
Springfield Clinic, LLP
Springfield, United States
Site US10007
Jeffersonville, United States
University of Kansas Medical Center
Kansas City, United States
Site US10066
Lenexa, United States
Site US10029
Towson, United States
Site US10032
St Louis, United States
Nebraska Medical Hospital
Omaha, United States
Site US10023
Omaha, United States
Site US10004
Hackensack, United States
Site US10024
Garden City, United States
Site US10055
New York, United States
Site US10059
New York, United States
Hudson Valley Urology, PC
Poughkeepsie, United States
Site US10053
Syracuse, United States
Site US10030
Chapel Hill, United States
Site US10062
Charlotte, United States
Site US10031
Greensboro, United States
Eastern Urological Associates
Greenville, United States
Site US10046
Winston-Salem, United States
Site US10035
Cincinnati, United States
Site US10022
Springfield, United States
Site US10027
Lancaster, United States
Site US10005
Pittsburgh, United States
Site US10018
Charleston, United States
Carolina Urologic Research Center
Myrtle Beach, United States
Site US10041
Nashville, United States
Site US10010
Dallas, United States
Site US10034
Houston, United States
Site US10043
Houston, United States
Site US10014
Norfolk, United States
Site US10015
Virginia Beach, United States
Virginia Mason Medical Center
Seattle, United States
Site US10038
Seattle, United States
Site US10021
Madison, United States
Site AR54005
Buenos Aires, Argentina
Site AR54007
Rosario, Argentina
Site AR54008
Buenos Aires, Argentina
Site AR54003
Cordorba, Argentina
Site AR54006
San Miguel de Tucumán, Argentina
Site AR54002
San Miguel de Tucumán, Argentina
Site AU61014
Albury, Australia
Site AU61001
Tweed Heads, Australia
Site AU61012
Wahroonga, Australia
Site AU61017
Wahroonga, Australia
Site AU61006
Ashford, Australia
Site AU61019
Ballarat, Australia
Site AU61007
East Bentleigh, Australia
Site AU61009
Malvern, Australia
Site AU61021
Parkville, Australia
Site AU61008
South Brisbane, Australia
Site AU61016
St Albans, Australia
Site AU61004
Westmead, Australia
Site AT43001
Vienna, Austria
Site BE32002
Kortrijk, Belgium
Site BE32009
Anderlecht, Belgium
Site BE32004
Brussels, Belgium
Site BE32005
Ghent, Belgium
Site BE32011
Ghent, Belgium
Site BE32007
Hasselt, Belgium
Site BE32008
Leuven, Belgium
Site BE32001
Liège, Belgium
Site BE32003
Turnhout, Belgium
Site BR55007
Porto Alegre, Brazil
Site BR55009
Bahia, Brazil
Site BR55008
Campinas, Brazil
Site BR55011
Jaú, Brazil
Site BR55002
Rio Grande, Brazil
Site BR55010
Santo André, Brazil
Site CA15003
Kingston, Canada
Site CA15021
Toronto, Canada
Site CA15001
Granby, Canada
Site CA15019
Abbotsford British Columbia, Canada
Site CA15020
Greenville, Canada
Site CA15011
Montreal, Canada
Site CA15017
Oakville, Canada
Site CA15022
Québec, Canada
Site CL56007
Santiago, Chile
Site CL56005
Santiago, Chile
Site CL56006
Viña del Mar, Chile
Site CL56004
IX Region, Chile
Site CL56002
Santiago, Chile
Site CL56001
Viña del Mar, Chile
Site CN86003
Hubei, China
Site CN86010
Hunan, China
Site CN86005
Nanjing, China
Site CZ42004
Olomouc, Czechia
Site CZ42002
Olomouc, Czechia
Site CZ42001
Prague, Czechia
Site CZ42003
Prague, Czechia
Site DK45002
Aalborg, Denmark
Site DK45003
Aarhus, Denmark
Site DK45001
Copenhagen, Denmark
Site DK45004
Herlev, Denmark
Site DK45006
Vejle, Denmark
Site FL35802
Tampere, Finland
Site FL35805
Turku, Finland
Site FR33021
Bordeaux, France
Site FR33008
La Roche-sur-Yon, France
Site FR33010
Lille, France
Site FR33002
Lyon, France
Site FR33020
Montpellier, France
Site FR33006
Nîmes, France
Site FR33003
Paris, France
Site FR33017
Paris, France
Site FR33001
Saint-Herblain, France
Site FR33019
Strasbourg, France
Site FR33022
Strasbourg, France
Site FR33004
Villejuif, France
Site GE99501
Tbilisi, Georgia
Site DE49004
Nürtingen, Germany
Site DE49007
Waldshut-Tiengen, Germany
Site DE49006
Mannheim, Germany
Site DE49001
Duisburg, Germany
Site DE49010
Bonn, Germany
Site DE49003
Hamburg, Germany
Site DE49013
Hamburg, Germany
Site HK85202
Hong Kong, Hong Kong
Site IL97205
Jerusalem, Israel
Site IL97202
Peth Tikva, Israel
Site IL97204
Ramat Gan, Israel
Site IL97203
Tzrifin Beer Yakov, Israel
Site IT39008
Faenza (RA), Italy
Site IT39001
Arezzo, Italy
Site IT39011
Candiolo, Italy
Site IT39004
Cremona, Italy
Site IT39002
Forlì, Italy
Site IT39005
Roma, Italy
Site IT39009
Toscana, Italy
Site IT39006
Trento, Italy
Toho University Sakura Medical Center
Sakura-shi, Japan
Kyushu University Hospital
Higashiku, Japan
Gunma University Hospital
Maebashi, Japan
Kagawa University Hospital
Kida-gun, Japan
Yokohama City University Medical Center
Yokohama, Japan
Kindai University Hospital
Sayama, Japan
Nippon Medical School Hospital
Bunkyo-ku, Japan
The Cancer Institute Hospital of Japanese Foundation for Cancer Research
Koutou-ku, Japan
Yamaguchi University Hospital
Ube, Japan
Chiba cancer center
Chiba, Japan
Harasanshin hospital
Fukuoka, Japan
Kyoto University hospital
Kyoto, Japan
Niigata University Medical and Dental Hospital
Niigata, Japan
Osaka Metropolitan University Hospital
Osaka, Japan
Site MY60001
Kuching, Malaysia
Site MD37301
Chisinau, Moldova
Site NL31010
Amsterdam, Netherlands
Site NL31009
Den Helder, Netherlands
Site NL31004
Maastricht, Netherlands
Site NL31011
Rotterdam, Netherlands
Site NZ64002
Auckland, New Zealand
Site NZ64005
Dunedin, New Zealand
Site NZ64001
Hamilton, New Zealand
Site NO47001
Stavanger, Norway
Site PL48002
Gdansk, Poland
Site PL48001
Mysłowice, Poland
Site PL48004
Pozman, Poland
Site PL48005
Słupsk, Poland
Site PL48011
Warsaw, Poland
Site PL48003
Wroclaw, Poland
Site RO40003
Bucharest, Romania
Site RO40001
Cluj-Napoca, Romania
Site RO40004
Cluj-Napoca, Romania
Site RU70008
Ivanovo, Russia
Site RU70001
Moscow, Russia
Site RU70005
Omsk, Russia
Site RU70009
Saint Petersburg, Russia
Site RU70003
Saint Petersburg, Russia
Site RU70006
Saint Petersburg, Russia
Site RS38102
Belgrade, Serbia
Site RS38101
Belgrade, Serbia
Site SK10223
Bratislava, Slovakia
Site SK42109
Košice, Slovakia
Site SK42106
Košice, Slovakia
Site SK42105
Nitra, Slovakia
Site SK42103
Prešov, Slovakia
Site SK42108
Trenčín, Slovakia
Site SK42107
Žilina, Slovakia
Site ZA27001
George, South Africa
Site KR82008
Busan, South Korea
Site KR82012
Seongnam-si, South Korea
Site KR82005
Seongnam-si, South Korea
Site KR82009
Seoul, South Korea
Site KR82007
Seoul, South Korea
Site KR82011
Seoul, South Korea
Site KR82001
Seoul, South Korea
Site KR82002
Seoul, South Korea
Site KR82003
Seoul, South Korea
Site KR82004
Seoul, South Korea
Site ES34007
Barcelona, Spain
Site ES34003
Barcelona, Spain
Site ES34011
Girona, Spain
Site ES34012
Madrid, Spain
Site ES34001
Madrid, Spain
Site ES34008
Madrid, Spain
Site ES34005
Pamplona, Spain
Site ES34014
Salamanca, Spain
Site ES34010
Santiago de Compostela, Spain
Site SE46001
Gothenburg, Sweden
Site SE46003
Umeå, Sweden
Site TW88607
Guishan, Taiwan
Site TW88603
Kaohsiung City, Taiwan
Site TW88601
Kaohsiung City, Taiwan
Site TW88602
Taichung, Taiwan
Site TW88606
Taipei, Taiwan
Site TH66001
Hat Yai, Thailand
Site TH66002
Bangkok, Thailand
Site TR90002
Beşevler, Turkey (Türkiye)
Site UA38004
Dnipro, Ukraine
Site UA38005
Kharkiv, Ukraine
Site UA38001
Kyiv, Ukraine
Site UA38003
Uzhhorod, Ukraine
Site GB44009
Bebington, United Kingdom
Site GB44003
Belfast, United Kingdom
Site GB44004
Bristol, United Kingdom
Site GB44014
Cambridge, United Kingdom
Site GB44005
Cardiff, United Kingdom
Site GB44002
Glasgow, United Kingdom
Site GB44006
London, United Kingdom
Site GB44007
Manchester, United Kingdom
Site GB44008
Northwood, United Kingdom
Site GB44016
Nottingham, United Kingdom
Site GB44001
Sutton, United Kingdom
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.